A 13-year-old splenectomized, multitransfused ␤-thalassemia major, male patient received an allogenic BMT from his HLA-compatible brother after suffering grade III regimen-related pulmonary toxicity. He developed features of CMV pneumonitis with positive pp65 CMV antigenemia involving 2.5% peripheral blood neutrophils from day ؉46. The patient received intravenous immunoglobulin and ganciclovir 5 mg/kg intravenously twice daily. His neutrophil count was maintained above 1 ؋ 10 9 /l by G-CSF 5 g/kg subcutaneously as and when required. From day 7 onwards following twice daily ganciclovir his peripheral blood smear started showing isolated cytoplasmic inclusions, 1-3 per neutrophil, 3-5 in diameter, involving 2-3% of the neutrophils and occasional monocytes. Transmission election microscopy of peripheral blood neutrophils showed type I and type II intranuclear inclusions. These inclusions disappeared within 48 h of stopping ganciclovir. Inclusions were not seen in three patients who were given prophylactic ganciclovir 5 mg/kg once daily for 5 days every week following allogenic BMT after the same conditioning regimen. These patients were also negative for CMV antigenemia. Development of type I and type II intranuclear inclusions in blood neutrophils in patients receiving ganciclovir therapy has not been reported previously, and the striking light microscopic changes provide simple morphological evidence of the toxic effect of this drug on blood neutrophils. Keywords: ganciclovir; CMV pneumonitis; inclusions; type I intranuclear inclusions; type II intranuclear inclusions; electron microscopy A 13-year-old splenectomized, multitransfused ␤-thalassemia major patient received an allogenic bone marrow transplant from his elder brother. He was conditioned with busulphan 16 mg/kg/p.o. over 4 days, cyclophosphamide Correspondence: Dr K Ghosh, Institute of Immunohematology, 13th floor, KEM Hospital Campus, Parel, Mumbai, 400012, India Received 24 December 1998; accepted 22 March 1999 50 mg/kg/i.v./day for 3 days and antilymphocytic globulin 12 vials given over 2 days. Cyclophosphamide on day 4 and antilymphocytic globulin on day 3 were not given as he developed grade III regimen-related lung toxicity and veno-occlusive disease of the liver. Both complications were managed along standard lines and the patient engrafted by day +9 with 0.5 × 10 9 /l neutrophils in the peripheral blood. He received cyclosporin and prednisolone as prophylaxis for GVHD, and was discharged from the BMT unit on day +28. He was followed up with regular CMV antigenemia tests on peripheral blood neutrophils using monoclonal antibody to viral phosphoprotein, pp-65 using Coulter multiparameter flow cytometer (Coulter Epics-XL-MCL, Coulter Electronics, Hialeah, FL, USA). On day +46, 2.5% of the peripheral blood neutrophils showed positive fluorescence against pp-65 and by day +49 the patient developed breathlessness, patchy opacities in both lung fields and desaturation of the peripheral blood (oxygen saturation on room air dropped to 85%). He became febrile and had an episode of convulsions with a normal EEG. A CT scan of the brain with contrast enhancement showed no focal abnormalities.
50 mg/kg/i.v./day for 3 days and antilymphocytic globulin 12 vials given over 2 days. Cyclophosphamide on day 4 and antilymphocytic globulin on day 3 were not given as he developed grade III regimen-related lung toxicity and veno-occlusive disease of the liver. Both complications were managed along standard lines and the patient engrafted by day +9 with 0.5 × 10 9 /l neutrophils in the peripheral blood. He received cyclosporin and prednisolone as prophylaxis for GVHD, and was discharged from the BMT unit on day +28. He was followed up with regular CMV antigenemia tests on peripheral blood neutrophils using monoclonal antibody to viral phosphoprotein, pp-65 using Coulter multiparameter flow cytometer (Coulter Epics-XL-MCL, Coulter Electronics, Hialeah, FL, USA). On day +46, 2.5% of the peripheral blood neutrophils showed positive fluorescence against pp-65 and by day +49 the patient developed breathlessness, patchy opacities in both lung fields and desaturation of the peripheral blood (oxygen saturation on room air dropped to 85%). He became febrile and had an episode of convulsions with a normal EEG. A CT scan of the brain with contrast enhancement showed no focal abnormalities.
Biochemical investigations showed mild elevation of the liver enzymes ALAT (82 IU/l) with a normal serum bilirubin level. There was no clinical evidence of GVHD. Complete blood counts done on several occasions showed Hb 9.4 gm/dl, WBC 2.6 × 10 9 /l, platelets 46 × 10 9 /l. Peripheral blood smears showed occasional eosinophils, many large granular lymphocytes, giant platelets and occasional nucleated red cells with target cells and Howell Jolly bodies. Neutrophils comprised 44% of the nucleated cells. There were many atypical lymphocytes.
The patient was too unfit to undergo bronchoalveolar lavage and was started on ganciclovir 5 mg/kg/twice daily for 3 weeks and intravenous immunoglobulin 500 mg/kg on alternate days, i.v. for 10 doses, then every week until day +120 after BMT. Whenever his neutrophil count dropped below 1 × 10 9 /l he received G-CSF, 5 g/kg subcutaneously so that regular ganciclovir administration was possible without discontinuation. By day 12 of ganciclovir therapy the patient became negative on the CMV antigenemia test and he improved clinically with interstitial changes on the chest X-ray and CT scan of the lungs. He became totally asymptomatic and was finally discharged from the hospital on day +124.
However, 7 days after twice a day ganciclovir therapy the patient started showing hypersegmentation of his neutrophils ( Figure 1d ) and macrocytosis. 3% of neutrophils (Figure 1a , b) and occasional monocytes (Figure 1c) showed round, basophilic single or multiple inclusions (3-5 ) or nuclear fragments separate from the segmented nucleus of the neutrophils or nucleus of the monocytes. Some of the inclusions had rod-like structures and some projected like a thread from the end of the nucleus (Figure 1d) .
A fresh sample of peripheral blood buffy coat was fixed in 2.5% paraformaldehyde and 2% glutaraldehyde in 0.1 N cacodylate buffer pH 7.38 at 4°C, placed in the refrigerator for 30 min and then prepared for electron microscopy. Transmission electron microscopy of the peripheral blood neutrophils showed inclusions in the neutrophil cytoplasm ( Figure 2 ) (type I) and inclusion of nuclear material within the nucleus (type II) (Figure 3 ). The inclusions in the neutrophils disappeared within 48 h of stopping ganciclovir therapy.
The patient was taking regular folic acid supplementation and was off trimethoprim-sulphamethoxazole during the treatment of his CMV pneumonia. His serum vitamin B12 and folic acid levels were in the normal range.
A karyotype done on aspirated marrow cells showed the normal 46, XY pattern.
Aspirated marrow showed mild megaloblastic erythropoiesis with normal maturation of myeloid and erythroid elements and megakaryocytes were present with normal morphology.
Discussion
Ganciclovir is extensively used in bone marrow transplantation practice either as prophylaxis against cytomegalovirus or for the treatment of CMV disease. Ganciclovir is a prodrug and has minimal toxicity on human cells as the drug is a poor substrate for human thymidine kinase in contrast to HSV thymidine kinase or the CMV UL97 gene product. Hence in cells where the CMV UL97 gene product is available due to active CMV infection or passive imbibition of the enzyme, ganciclovir may be converted into toxic ganciclovir phosphate.
The morphological findings described of cytoplasmic inclusions in the neutrophils and monocytes under light microscopy and the presence of type I and type II nuclear inclusions on transmission electron microscopy has not been reported to date. However, similar findings have been reported in the lymphoid cells of Burkitts lymphoma, 1 in various leukemias and in myelodysplastic syndromes, 2, 3 and in the neutrophils of patients treated with cytosine arabinoside 4 and 5-fluorouracil. 5 These kinds of inclusions have been related to aneuploidy in acute leukemia. 6 The fact that ganciclovir can be converted into a cytotoxic antimetabolite in virus-infected cells much like cytosine arabinoside and 5-fluorouracil within malignant cells, suggests that similar mechanisms may be operative in case of gan- Figure 3 Type II intranuclear inclusion in a neutrophil (arrow). Electron dense intranuclear material is surrounded by a dense chromatin band discriminating it from a pseudoinclusion (× 15 000).
ciclovir-induced inclusions within neutrophils. The detailed mechanism of formation of such inclusions has been discussed extensively in standard textbooks on electron microscopy.
7 Figure 1d shows how elongation of a nuclear process may possibly result in type I cytoplasmic inclusions in the nucleus.
Only 2-3% of the circulating neutrophils and occasional monocytes showed abnormal inclusions. However, even after an extensive search lymphocytes were found to be free of these inclusions. As 2-3% of the peripheral blood neutrophils also showed CMV antigenemia it is tempting to speculate that the same cells may be vulunerable to ganciclovir toxicity-related morphological changes.
After observing the striking changes in the neutrophils of the index patient taking ganciclovir, we carefully examined the blood smears of another three patients who were receiving once daily, 5 days a week prophylactic ganciclovir, with negative CMV antigenemia on flow cytometry. All these patients showed mild nuclear changes in the form of sessile bodies and irregular nuclear membranes. None of these changes were as striking as that of the present case.
Transmission electron microscopy on the peripheral blood of these three patients receiving prophylactic ganciclovir therapy failed to show the nuclear inclusions described in the present case.
Our patients received G-CSF only when the peripheral white cell counts dropped to Ͻ1 × 10 9 /l. There were times when the patient was without G-CSF for 2-3 days, and as we know the effect of G-CSF is short lasting and the halflife of neutrophils in the peripheral circulation is only a few hours it can be concluded that the G-CSF probably did not contribute to the production of the neutrophil inclusions.
The patient had also been splenectomized. In splenectomized patients, many red cell abnormalities are seen in the peripheral blood because of the absence of the pitting and culling effects of the spleen. The neutrophils with inclusions could similarly have been trapped if the patient had an intact spleen, making them unlikely to be found in the peripheral blood.
The inclusions described here are not morphologically akin to cytomegalovirus themselves and they persisted even though the CMV antigenemia resolved. Persistence of these inclusions was related to the twice daily ganciclovir infusions and the inclusions disappeared within 48 h of stopping the drug thus proving that the inclusions were linked to the intensity of ganciclovir therapy rather than to anything else. The ultrastructure changes of ganciclovir toxicity in the present case were striking but light microscopy changes offer a convenient and simple method of assessing the toxic effect of this drug on neutrophils.
